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Abstract: Gene therapy and DNA vaccination are among the most expected biotechnological and
medical advances for the coming years. However, the lack of cost-effective large-scale production
and purification of pharmaceutical-grade plasmid DNA (pDNA) still hampers their wide application.
Downstream processing, which is mainly chromatography-based, of pDNA remains the key manu-
facturing step. Despite its high resolution, the scaling-up of chromatography is usually difficult and
presents low capacity, resulting in low yields. Alternative methods that are based on aqueous two-
phase systems (ATPSs) have been studied. Although higher yields may be obtained, its selectivity
is often low. In this work, modified polymers based on poly(ethylene glycol) (PEG) derivatisation
with amino groups (PEG–amine) or conjugation with positively charged amino acids (PEG–lysine,
PEG–arginine, and PEG–histidine) were studied to increase the selectivity of PEG–dextran systems
towards the partition of a model plasmid. A two-step strategy was employed to obtain suitable pure
formulations of pDNA. In the first step, a PEG–dextran system with the addition of the affinity ligand
was used with the recovery of the pDNA in the PEG-rich phase. Then, the pDNA was re-extracted to
an ammonium-sulphate-rich phase in the second step. After removing the salt, this method yielded a
purified preparation of pDNA without RNA and protein contamination.
Keywords: aqueous two-phase systems; affinity partition; non-viral vectors; plasmid DNA purifica-
tion; gene therapy; DNA vaccines
1. Introduction
The increasing development of molecular biotechnology and molecular therapies,
such as non-viral gene therapy and DNA vaccines, is reflected in an imperative demand
for large amounts of plasmid DNA (pDNA) with a stringent clearance of impurities [1,2].
In both cases, pDNA plays a very important role as a non-viral vector. The use of this type
of vector was extensively described for the expression of therapeutic proteins both in vitro
and in vivo, making them important tools for gene therapy [3,4]. Moreover, pDNA vectors
can stimulate humoral and cellular immune responses to a specific antigen, allowing for
the development of DNA vaccination [5]. This was recently in the spotlight, with several
DNA vaccines being developed against SARS-CoV-2 [6,7]. Although most of them are
still in clinical trials, one plasmid-based vaccine for COVID-19 was recently approved in
India [8]. In this regard, it is also worth mentioning that two DNA-based vaccines that
use adenovirus as vectors (commercialised by Astra-Zeneca and Janssen) were already
approved for clinical use in several countries around the world, including the European
Union [9]. This opens good perspectives for the wide use of this vaccine strategy.
Life 2021, 11, 1138. https://doi.org/10.3390/life11111138 https://www.mdpi.com/journal/life
Life 2021, 11, 1138 2 of 16
The wide application of pDNA requires adequate methods for its production and
mostly for its large-scale purification. Consequently, the current biggest challenge consists
in developing an efficient and cost-effective scalable purification process [10]. Currently,
large-scale pDNA purification is mainly based on traditional chromatography methods,
which provide final pDNA fractions that are separated from impurities, as well as un-
desired plasmid isoforms. Usually, ion exchange (IEC), hydrophobic interaction (HIC),
and size-exclusion chromatography (SEC) are used, both in single or sequential mode, to
meet all the regulatory requirements for pharmaceutical grade plasmids [10]. However,
despite being widely used and the standard approach with an unmatched high resolu-
tion, chromatography-based techniques still have some disadvantages. These are mostly
due to the long separation times and low capacity, which are related to problems with
access and mass transfer within solid-phase chromatography matrices for large molecules,
such as plasmids [11]. Furthermore, despite their high resolution, these techniques have
high operational costs, require preliminary steps of purification, and their scale-up is fre-
quently difficult to establish, which decreases the purification outcome [12,13]. Since large
quantities of pDNA are needed for clinical use and due to its increasing number of applica-
tions, there is a need for more efficient and cost-effective processes for the production and
downstream processing of pDNA of pharmaceutical grade [14].
Alternative downstream strategies have already been developed and implemented.
On the one hand, new highly porous solid materials, known as monoliths, were tested
to increase the capacity of the chromatographic systems. On the other hand, different
separation methods, such as precipitation, extraction by organic solvents or aqueous two-
phase systems (ATPSs), or even ultrafiltration, are widely implemented at the lab scale
with relatively good yields and were tested for the large-scale purification of pDNA. Un-
fortunately, most of these alternatives are time-consuming, require hazardous chemicals or
non-certified enzymes, neglect the regulatory guidelines, and are not scalable. Remarkably,
ATPSs, which are a type of liquid–liquid extraction, have been used for the recovery and
partial purification of a variety of biological products at different scales, making them a
very promising alternative for pDNA purification [15,16]. ATPSs result from the mixture of
two different polymers or a polymer and a salt in concentrations higher than critical values,
forming two phases with different physical and chemical properties, which allows for the
separation of components in a complex mixture [17]. This method presents advantages
over the chromatography-based approaches, such as operational simplicity, easy scale-
up, potential integration in a continuous process, low cost, capacity to integrate different
process steps in one operation, and biocompatibility [18–21].
Although these systems are usually less selective when compared with the conven-
tional methods, their selectivity may be improved by introducing a specific ligand to steer
the biomolecule of interest into one of the phases [22]. In this approach, called affinity
partition, the presence of affinity ligands, i.e., molecules with specificity and biorecognition
properties towards a target solute, allows for the extraction of the target from a crude
feedstock despite possible similarities with the contaminants [22].
ATPSs were already successfully used in a multitude of purification processes. These
range from products for therapeutic purposes, such as antibodies, hormones, and en-
zymes [23–33], to others used in industrial applications, with emphasis on enzymes [34,35]
and other proteins [36] employed in the food industry. In addition, they were also useful in
recycling wastewater in the food, dairy, beverage, pharmaceuticals, dyeing, tannery, and
metal-processing industries [37]. The implementation of ATPSs for pDNA purification
was reported at different scales [38–44]. However, its utilisation is usually restricted to the
first purification steps due to the low selectivity of the systems. The increase in selectivity
was achieved by using specific ligands for pDNA. The cationic polymer polyethyleimine
(PEI) derivatised with poly(ethylene glycol) (PEG) was used in PEG–dextran systems to
selectively recover the pDNA in the polyplex form [45]. Although the polyplexes yield was
very good (100%), attempts to separate them from the phase forming polymers via ultrafil-
tration resulted in adsorption to the membrane and very low final recovery. Alternatively,
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a protein-based ligand with glutathione-S-transferase protein (GST) fused to a zinc finger
transcription factor (ZnF), designated GST-ZnF, was able to isolate pDNA with the ZnF
recognition site in a PEG–dextran ATPS [46]. However, the pDNA was not eluted from the
complex. The DNA-binding fusion protein LacI–His6–GFP, together with the conjugate
PEG–IDA–Cu(II), was tested as an affinity ligand in PEG–dextran ATPSs [47]. Similarly,
the elution of the pDNA was found to be the critical step and only 27% of plasmid recovery
was achieved. Recently, the performance of a synthetic oligonucleotide that was employed
as affinity ligand towards the plasmid vector pUC118 was described in PEG–sodium sul-
phate systems [48]. Although significantly good results were reported, namely 67% pDNA
recovery, this approach is highly dependent on the nucleotide sequences of both elements
to promote the recognition.
Interactions of proteins with nucleic acids are ubiquitous in nature, as they are the
base of many fundamental biochemistry processes, such as DNA replication, transcription,
and translation. These interactions are mediated by the amino acids that are present in the
proteins and involve van der Waals interactions and several hydrogen bonds and water-
mediated bonds [49]. Positively charged amino acids, such as lysine and arginine, mediate
most interactions between proteins and nucleic acids, with interactions with guanine being
overrepresented within all the amino acids groups [50]. The strong interaction of positively
charged amino acids, such as lysine, arginine, and histidine, with nucleic acids was already
explored in chromatographic separations of these biomolecules. The amino acids were
used as affinity ligands that were bound to agarose supports for the purification of both
pDNA and RNA [51,52]. The obtained results were very promising and indicate that these
amino acids are good ligands for pDNA purification [51,53–59]. Purification processes
were reported with yields of 45% for lysine and histidine and 79% for arginine. For all
ligands tested, pDNA was recovered from the matrix without contaminants (more than
97% purity) [53,55].
Taking this into account, the main goal of this work was to screen four different
PEG–amino affinity ligands to attempt to increase the selectivity of PEG 600 and dextran
100 ATPSs by adding affinity ligands based on the derivatisation of PEG with amino
groups (PEG–amine) or conjugated with positively charged amino acids (PEG–lysine,
PEG–arginine, and PEG–histidine) towards pDNA.
2. Materials and Methods
2.1. Materials
The model plasmid used was pVAX1/LacZ type ColE1 with 6050 bp, which was
designed by Invitrogen (Carlsbad, CA, USA) for the development of DNA vaccines. Es-
cherichia coli DH5α from Invitrogen was used as the host for this plasmid. Genetically
modified E. coli DH5α (ackA-pta) (poxB), transformed with the NTC7482-41H-HA plasmid
(6212 bp), were provided courtesy of the Nature Technology Corporation–Biologics by
Design (Lincoln, NE, USA). PEG MW 600 (PEG 600), dextran 100,000 g·mol−1 (dextran
100), and methoxypolyethylene glycol amine 5000 (PEG–amine) were obtained from Sigma-
Aldrich (St. Louis, MO, USA). Lysine, arginine, and histidine were obtained from BDH
Chemicals (Poole, UK). All the other reagents used were of analytical grade.
2.2. Poly(Ethylene Glycol)–Amine Affinity Ligands Synthesis
2.2.1. Methoxypolyethyleneglycol–Lysine and –Arginine
To an ice-cooled solution of PEG–amine in dichloromethane, Boc-Lys(Boc)-OH (or
Boc-Arg(Pbf)-OH), hydroxybenzotriazol (HOBt), and dicyclohexylcarbodiimide (DCC)
were sequentially added. The reaction mixtures were stirred in an ice bath for 2 h, allowed
to reach room temperature (around 23 ◦C), and further stirred overnight. The precipi-
tated dicyclohexylurea (DCU) was filtered off and both dichloromethane solutions were
concentrated under reduced pressure. The slow addition of diethyl ether to the stirring
dichloromethane solutions gave rise to copious white solids. The precipitates were collected
via filtration, redissolved in dichloromethane, and precipitated again by adding diethyl
Life 2021, 11, 1138 4 of 16
ether. This procedure was repeated twice. The white solids were dried at room temperature
overnight, dissolved in hydrochloric acid, and the solutions were left stirring at room
temperature overnight. The solvent was removed at reduced pressure at room temperature
to afford a light yellow vitreous solid. The solids were dissolved in dichloromethane and
precipitated under stirring by adding diethyl ether. The final precipitates (PEG–lysine and
PEG–arginine) were filtered off and dried at room temperature. The derivatisation of the
polymers was confirmed using 1H NMR spectroscopy.
2.2.2. Methoxypolyethyleneglycol–Histidine
To an ice-cooled solution of PEG–amine in dichloromethane, 1.2 equivalents of diciclo-
carbodiimide, 1.2 equivalents of hydroxibenzotriazol, and 1.2 equivalents of Boc-histidine
were sequentially added. The reaction mixture was stirred for 16 h and then filtered
and totally dried under reduced pressure. The precipitate was collected, redissolved in
ethyl acetate, and extracted with potassium bisulphate (step repeated three times). The
aqueous phase was acidified up to pH 7.0 and the final compound was extracted with
dichloromethane (step repeated three times). The organic phase was completely evap-
orated, PEG–histidine was dissolved in dichloromethane and trifluoroacetic acid, and
the reaction mixture was stirred for 16 h. In the end, the solution was evaporated under
reduced pressure, the compound precipitated with petroleum ether, and finally filtered.
The derivatisation of the polymer was confirmed using 1H NMR spectroscopy.
2.3. Plasmid Production
E. coli DH5α, previously transformed with plasmid pVAX1/lacZ, was grown in Luria-
Bertani (LB) medium (yeast extract 0.5% (w/v), triptone 1% (w/v), and sodium chloride
0.5% (w/v), pH 7.4) with 30 µg·mL−1 of kanamycin, obtained from Sigma-Aldrich (St.
Louis, MO, USA). The cultures were incubated at 37 ◦C and 180 rpm, overnight. The cells
were harvested via centrifugation (4500× g, 10 min, 4 ◦C) at the end of the exponential
phase and then stored at −20 ◦C.
2.4. Alkaline Cell Lysis
The cell lysate was prepared as described by Ribeiro et al. [39] (slightly modified, as
reported by Sambrook [60]). Briefly, a bacterial pellet corresponding to 250 mL of bacterial
culture was resuspended in 12.5 mL of a solution containing 50 mM glucose, 25 mM
Tris-HCl, and 10 mM EDTA, pH 8.0. The suspension was gently stirred for 10 min in an
ice bath while slowly adding 12.5 mL of a solution of 1% (w/v) SDS and 200 mM sodium
hydroxide for the lysis to occur. Then, the solution was neutralised with 9.4 mL of a
solution containing 3 M potassium acetate and 11.5% (v/v) acetic acid. The final mixture
was centrifuged at 15,000× g for 20 min at 4 ◦C. The obtained supernatant, named lysate,
was stored at −20 ◦C.
2.5. Lysate Desalting
A PD-10 Desalting Column from GE Healthcare Biosciences (Pittsburgh, PA, USA)
was used for the cell lysate desalinisation. The column was first equilibrated with 25 mL of
Tris-HCl (50 mM, pH 7.5 or 8.5). Then, 2.5 mL of the alkaline lysate added to the column
was eluted with 3.5 mL of the same buffer, resulting in the collection of 3 mL of desalted
lysate. The desalted lysate was stored at −20 ◦C.
2.6. Aqueous Two-Phase Experiments
Polymer–polymer ATPSs composed of 16.2% (w/w) PEG 600 and 17.4% (w/w) dextran
100 were prepared by mixing suitable amounts of each component’s stock solution. A total
of 20% (w/w) of desalted E. coli lysate was added by considering the total system’s weight.
Increasing amounts of PEG–amino affinity ligand were added and the desired total weight
of the systems was adjusted with water. The components were mixed using tube inversion
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and vortexed. To accelerate the two phases’ settling, the mixtures were then centrifuged at
3000× g for 30 min at 25 ◦C.
2.7. Extraction with an Ammonium-Sulphate-Rich Phase
The top phases of the previously prepared 16.2% (w/w) PEG 600–17.4% (w/w) dextran
100 systems were recovered and then mixed with a new phase containing ammonium
sulphate. For this purpose, the necessary amounts of salt and PEG 600 were calculated
to obtain a new system with a final composition of 20% (w/w) PEG 600 and 15% (w/w)
ammonium sulphate. This new system was used by Trindade et al. [40], yielding most of
the pDNA in the bottom phase. The calculations were based on the addition of a lower
phase with the same weight as the recovered upper phase. The partitioning experiments
with the new systems were performed as previously described.
2.8. Nucleic Acids Partitioning Analysis by Agarose Gel Electrophoresis (AGE)
Samples from the top and bottom phases were analysed in 1% (w/v) agarose gels in
the presence of ethidium bromide (EtBr). The loaded samples (10 µL) were prepared by
mixing 2 µL of the loading solution buffer containing bromophenol and glycerol to 10 µL
of the phase sample. The gels were run for 55 min in 90 V and 60 A in the presence of a
TAE buffer (40 mM Tris-base, 20 mM acetic acid, and 1 mM EDTA, pH 8.0). They were
then photographed using the gel documentation software Quantity One 1-D analysis from
Bio-Rad (Hercules, CA, USA).
2.9. Total Protein Partitioning Analysis Using Polyacrylamide Denaturing Gel Electrophoresis
(SDS–PAGE)
Samples of each ATPSs’ phase were evaluated in polyacrylamide denaturing gels (4%
(w/v) stacking gels with Tris-HCl 0.5 M, pH 6.8, and 10% (w/v) resolving gels with 1.5 M
Tris-HCl, pH 8.8). Samples were mixed with the sample buffer (0.5 M Tris-HCl, pH 6.8,
10% (w/v) SDS, 0.5% (w/v) bromophenol blue, and glycerol) and heated in a boiling water
bath (95 ◦C) for 4 min to achieve the total denaturation before loading. The gels were run
for 40 to 50 min at 170 V and 50 mA in the presence of the running buffer (3.03% (w/v) Tris,
14.4% (w/v) glycine, and 1% (w/v) SDS) [61,62]. Silver staining was used to visualise the
protein bands in the gels [63,64].
2.10. Total Protein Quantification
The total protein content present in each of the ATPSs’ phases was quantified using
the Bradford method, as described by Bradford [65]. The samples were read against blanks,
which were prepared as follows. For the blank correspondent to the lysate, a mixture of the
buffers used in its preparation was created with the same final composition, excluding the
bacterial cells. Then, bottom and top blank samples were obtained by preparing ATPSs
with the same composition but replacing the cell lysate with the previous blank mixture.
Concentrations were determined from a calibration curve using bovine serum albumin
(BSA, Sigma) as the standard.
2.11. Densitometric Analysis of Agarose Gel Bands
ImageJ 1.8 software (U.S. National Institutes of Health, Bethesda, MD, USA) [66,67]
was used to compare the intensities of the pDNA and RNA bands on the agarose gels,
where the top and bottom phases of the second ATPS (20% (w/w) PEG 600 and 15%
(w/w) ammonium sulphate were analysed. The images of the gels collected from the gel
documentation software Quantity One 1-D (Bio-Rad) were used for this analysis. The
recommendations in the ImageJ User Guide for densitometry were followed, with some
modifications, as described next. First, the images were adjusted to the 32-bit mode and the
look-up table (LUT) was inverted. Then, the lanes of the gels containing the corresponding
pDNA and RNA bands were selected using the Rectangular Selection tool. The profile
plot representing the relative densities of the bands contained in the selected area was
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obtained using the Plot Lanes function of the Analyze Gels tool. The area of each peak,
corresponding to each band, was measured with the help of the Wand tool. The Label
Peaks function (Analyze Gels tool) was used to label each peak with its size, expressed as a
percentage of the total size of all of the analysed peaks.
3. Results and Discussion
3.1. Specificity of PEG–Amino Affinity Ligands
PEG–dextran systems are among the most well-studied polymer–polymer two-phase
systems. Their use for the separation and recovery of several biomolecules has been
reported throughout the years. However, until now, there are no works reporting the
application of this type of ATPS to efficiently separate pDNA molecules. This may be
related to the subtle differences between the physicochemical properties of the two phases
of polymer–polymer ATPSs, which makes them less suitable for separation applications [68].
Their low selectivity highly hampers the separation of pDNA molecules from complex
mixtures, such as crude cell lysates.
Kepka and co-workers reported that, in PEG–dextran systems, all the main biomolecules
that are present in E. coli lysate accumulate in the bottom phase [69]. Based on these findings,
a PEG–dextran system was selected to test the purification of pDNA from crude cell lysates,
based on an affinity partition approach. First, it was hypothesised that the PEG–amino
affinity ligands would accumulate in the top PEG-rich phase of the PEG–dextran system
due to physicochemical similarities with the top phase forming polymer PEG. Furthermore,
the partition of the ligands to the top phase would be followed by the accumulation of the
pDNA in the same phase.
The PEG–amino affinity ligands shown in Figure 1 were carefully chosen based on the
results reported in previously reported affinity chromatography studies. In these studies,
the capacity of positively charged amino groups to interact with the negatively charged
pDNA molecules was demonstrated [59,70]. In the present study, the affinity ligands
were obtained by derivatisation of PEG chains with amino groups (PEG–amine) or by
conjugation with positively charged amino acids (PEG–lysine, PEG–arginine, and PEG–
histidine). All ligands were positively charged due to the presence of the amino groups.
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Figure 1. Poly(ethylene glycol)–amino ligands chemical structure: (a) PEG–amine; (b) PEG–lysine;
(c) PEG–arginine, and (d) PEG–histidine.
Considering the differences in the superficial charges of the ligands and the plasmid
(negatively charged because of the phosphate groups), it was expected that the two species
would interact electrostatically. This was certainly true for PEG–amine, but regarding the
conjugated ligands, it is known that other types of interactions may occur. Although the
mechanisms of pDNA biorecognition may differ between the affinity ligands, the result
was expected to be the same. Since the ligands are based on PEG chains, they should
accumulate in the top phase of the system (PEG-rich phase) and therefore be able to pull
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all pDNA molecules to this phase, keeping the remaining contaminants, mainly RNA and
proteins, in the bottom dextran-rich phase.
Therefore, the first part of this work comprised a concentration screening for each
ligand in the PEG–dextran systems to find the minimum ligand concentration that was
needed to separate the pDNA from the other contaminants. Figure 2 shows the results for
the pDNA and RNA partition in systems with increasing concentrations of PEG–amine,
PEG–lysine, PEG–arginine, and PEG–histidine.
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From the AGE analysis, it was clearly seen that, in the absence of an affinity ligand,
all the nucleic acids accumulated in the bottom phase of the ATPSs. However, as the
concentration of affinity ligand increased in the systems, pDNA molecules started to be
steered to the top phases, verifying our initial hypothesis.
After the initial screening, the following minimum percentages of ligand were defined:
6.5% (w/w) PEG–amine, 1.2% (w/w) PEG–lysine, 0.5% (w/w) PEG–arginine, and 1.3%
(w/w) PEG–histidine (note that the ligand percentage was related to the total percentage of
PEG in the system).
Molecular dynamics models revealed that several amino acid–nucleotide interactions
may occur [49,50]. The lysine lateral side chain length promotes interactions in different
conformations, producing good geometries that allow for strong hydrogen bonds. Molec-
ular modelling studies reported that, in protein–DNA interactions, lysine can promote
complex hydrogen bonds preferentially with guanine [50]. Furthermore, lysine N atoms
were found to be able to work both as acceptors and donors of hydrogen atoms [49].
Due to arginine’s property, namely, its ability to interact in different conformations,
its side chain length and its tendency to form strong hydrogen bonds could be pointed
to as the key mechanisms for the biorecognition of plasmids [49]. In fact, some studies
reported the establishment of strong arginine-mediated interactions between proteins and
nucleic acids [49,50]. Moreover, it was stated that the biorecognition of pDNA molecules
could be due to many elementary interactions between the backbone of plasmids and/or
involving the nitrogen bases [71]. It was also reported that the supercoiled structure of the
pDNA molecules favours multiple contacts with the ligands and promotes more complex
interactions between the two species [59].
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Finally, regarding histidine, it was discussed by Sousa et al. [59] that this amino acid
seems to interact with the exposed nitrogen bases of pDNA instead of its backbone. Several
types of interactions seem to lead to histidine–pDNA binding, namely, hydrogen bonds,
hydrophobic, imidazole ring- and water-mediated interactions, ring stacking, and van der
Waals forces [49,50].
Even though the addition of the ligands led to an increase in the ATPSs’ selectivity
towards pDNA, another phenomenon was identified. A residual amount of an unknown
species of RNA was detected in the top phases of the systems along with pDNA. Remark-
ably, it was found that this RNA species was first steered to the top phase of the systems for
lower ligand concentrations rather than the pDNA. These results suggest that even though
the ligands showed an affinity for the pDNA, they seemed to have even more affinity to
a certain type of RNA. A similar phenomenon was found in the affinity chromatography
experiments using immobilised positively charged amino acids as affinity ligands. The
authors reported higher relative retention factors for RNA than for pDNA for all the ligands
except for arginine [55].
3.2. pDNA Extraction with an Ammonium-Sulphate-Rich Phase
The first evaluation of the affinity ligands showed that all of them could be used in a
preliminary step of purification of pDNA or a multi-stage purification process, but not a
single-step process. Thus, a second extraction was performed in an attempt to separate the
pDNA from the remaining RNA.
PEG–ammonium sulphate ATPSs, previously studied by [40], were chosen based on
the published results concerning their separation yields. Trindade and co-workers reported
that a 20% (w/w) PEG 600–15% (w/w) ammonium sulphate system allows for the recovery
of 80.6% of pDNA, protein, and RNA free in the bottom phase relative to the initial lysate
(20% w/w load) [40].
Therefore, a second extraction with a bottom ammonium-sulphate-rich phase was
tested to verify whether the pDNA partition could be shifted. In this new system, it was
expected that the accumulation of pDNA would be in the bottom phase, while the remain-
ing contaminants would partition to the upper phase. The results of these experiments are
shown in Figure 3, where samples of each phase of the first and the second ATPS were
analysed using AGE.
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the second system was prepared to have a phase volume ratio of 1.1, higher ratios were 
observed. As the volume of the bottom phase of the second system has drastically de-
creased, the partitioning phenomenon may have occurred differently, affecting the distri-
bution of the biomolecules [72]. 
Table 1 shows the quantification results of the AGE bands corresponding to the par-
tition of pDNA and RNA after re-extraction with the second system. The results obtained 
after the densitometric analysis of the agarose gels with the image processing software 
corroborated the conclusions drawn before. The software could neither detect nor quan-
tify any bands corresponding to RNA in the bottom phases of the systems where PEG–
lysine and PEG–arginine were added. 
Table 1. Characterisation of the nucleic acids band intensities after the AGE analysis of the parti-
tioning of pDNA and RNA with the re-extraction system (20% (w/w) PEG 600–15% (w/w) ammo-
nium sulphate). 
 6.5% PEG–Amine 
 
Top Phase Bottom Phase 
Band Area Percentage Band Area Percentage 
pDNA 4525.3 5.1 58908.5 74.1 
RNA 84927.4 94.9 20622.5 25.9 
 1.2% PEG–Lysine 
 Top Phase Bottom Phase 
Fi garose gel lectrophoresis (AGE) analysis of nucleic acids partitioning in subsequent
systems composed of (1) 16.2% (w/w) PEG 600–17.4% (w/w) dextran 100 with 20% (w/w) of desalted
bacterial lysate (pH = 7.5 or 8.5) with the corresponding affinity ligand percentage and (2) 20% (w/w)
PEG 600–15% (w/w) ammonium sulphate systems. (L) Desalted lysate. The original AGE is shown
in Figures S5–S8 of the Supplementary Materials.
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In all cases, a significant plasmid–RNA separation was achieved after performing
the second extraction. Despite RNA being completely removed in the systems containing
PEG–lysine and PEG–arginine, it was still possible to see a vestigial amount of it in the
bottom phases of the second systems (where pDNA accumulates) when PEG–amine and
PEG–histidine were used. Similarities between the molecular weight and the net charge
of some RNA molecules or fragments and pDNA may explain why, in these systems,
the former ones were more suitable to partition to the salt-rich phase. Moreover, even
though the second system was prepared to have a phase volume ratio of 1.1, higher ratios
were observed. As the volume of the bottom phase of the second system has drastically
decreased, the partitioning phenomenon may have occurred differently, affecting the
distribution of the biomolecules [72].
Table 1 shows the quantification results of the AGE bands corresponding to the
partition of pDNA and RNA after re-extraction with the second system. The results
obtained after the densitometric analysis of the agarose gels with the image processing
software corroborated the conclusions drawn before. The software could neither detect
nor quantify any bands corresponding to RNA in the bottom phases of the systems where
PEG–lysine and PEG–arginine were added.
Table 1. Characterisation of the nucleic acids band intensities after the AGE analysis of the parti-
tioning of pDNA and RNA with the re-extraction system (20% (w/w) PEG 600–15% (w/w) ammo-
nium sulphate).
6.5% PEG–Amine
Top Phase Bottom Phase
Band Area Percentage Band Area Percentage
pDNA 4525.3 5.1 58,908.5 74.1
RNA 84,927.4 94.9 20,622.5 25.9
1.2% PEG–Lysine
Top Phase Bottom Phase
Band Area Percentage Band Area Percentage
pDNA 0 0 50,694.5 100
RNA 43,254.3 100 0 0
0.5% PEG–Arginine
Top Phase Bottom Phase
Band Area Percentage Band Area Percentage
pDNA 0 0 48,787.4 100
RNA 54,061.7 100 0 0
1.3% PEG–Histidine
Top Phase Bottom Phase
Band Area Percentage Band Area Percentage
pDNA 0 0 47,470.7 81.3
RNA 30,013.5 100 10,904.5 18.7
0.5% PEG–Arginine (Scale-Up)
Top Phase Bottom Phase
Band Area Percentage Band Area Percentage
pDNA 0 0 29,553.5 77.5
RNA 39,394.4 100 8601.0 22.5
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Table 1. Cont.
0.5% PEG–Arginine (High-Yield Cell Lysate)
Top Phase Bottom Phase
Band Area Percentage Band Area Percentage
pDNA 0 0 24,504.4 81.8
RNA 28,249.9 100 5453.5 18.2
3.3. Protein Contamination Assessment
Concerning the protein fraction that was present in the cell lysate (170.09 µg·mL−1
in non-desalted lysates and 104.66 µg·mL−1 in the desalted lysates; total protein content
quantified using the Bradford Method [65,73]), its partition behaviour was assessed using
SDS–PAGE (Figure 4).
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Figure 4. SDS–PAGE electrophoresis analysis of the total proteins partitioning in subsequent systems co posed by (1) 16.2%
(w/w) PEG 600–17.4% (w/w) dextran 100 with 20% (w/w) desalted bacterial lysate (pH = 7.5 or 8.5) with the corresponding
affinity ligand percentage and (2) 20% (w/w) PEG 600–15% (w/w) ammonium sulphate systems. (L) Desalted lysate. The
original SDS–PAGE is shown in Figures S9–S12 of the Supplementary Materials.
It was possible to conclude that, after the first partition experiment, most of the
proteins were accumulated in the bottom phase of the systems. This meant that, after the
first step of the purification, the proteins were almost completely removed. In the second
system, the remaining proteins were retained in the top phase, leaving the pDNA (collected
in the bottom phase) free of its contamination.
3.4. Process Scale-Up and Capacity Assessment
Once the biorecognition capacity of each amino affinity ligand was assessed, PEG–
arginine was selected for further tests. To verify whether the purification outcome of this
two-step process was the same in a larger system, the scale of the systems was increased
between 2 and 20 times. Figure 5a shows the AGE results for the biggest system tested
(10 g). The results from the scale-up experiment confirmed that there were no changes
in the partition behaviour of the pDNA molecules during the process. These findings
corroborate the well-known theoretical concepts around ATPSs as a separation technique,
which state that this methodology is easily scaled up. Furthermore, this experiment can
be used as a proof of concept of the affinity approach for plasmid purification from crude
cell lysates.
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Figure 5. Agarose gel electrophoresis (AGE) analysis of nucleic acids partitioning in subsequent
systems composed by (1) 16.2% (w/w) PEG 600–17.4% (w/w) dextran 100 with 20% (w/w) of desalted
bacterial lysate, pH = 7.5, and with 0.5% (w/w) PEG–arginine; and (2) 20% (w/w) PEG 600–15% (w/w)
ammonium sulphate systems. (L) Desalted lysate; (L*) non-desalted lysate; (a) samples from the
scale-up experiments; (b) samples from experiments with high-yield pDNA cell lysate. The original
AGE is shown in Figures S13 and S14 of the Supplementary Materials.
Additionally, to assess the capacity of the systems, a new pDNA-concentrated cell
lysate was used. This new lysate was obtained from the alkaline lysis of a genetically
modified E. coli strain, namely, DH5α (ackA-pta) (poxB), which is known to be a high
pDNA producer. The results, represented in Figure 5b, expressed the high capacity of
the systems under study since the same results for biomolecules’ partition were obtained.
Once again, the well-known high capacity of ATPSs was shown with this experiment.
However, it is important to mention that a vestigial amount of RNA contaminating the
pDNA-containing bottom phase of the second system was seen in both tests. This suggests
that the concentration of the ligand might have to be optimised depending on the scale
and pDNA concentration. Alternatively, a final polishing step might have to be introduced
to attain a higher degree of purification, particularly in larger-scale applications.
4. Conclusions
In this work, it was demonstrated that positively charged amino acids that were
conjugated to PEG chains could be used as affinity ligands for the purification of pDNA in
ATPSs. Moreover, the commercial polymer PEG–amine was shown to have the capacity to
biorecognise the molecules of pDNA. However, the interaction of these ligands with the
pDNA was different for each ligand, which was reflected in the differences in the amounts
of ligands needed.
Regarding the application of amino acids for pDNA purification in affinity chromatog-
raphy, it was reported that the performances of the lysine and histidine were very similar
(recovery yield of 45%) and that arginine was the best ligand (recovery yield of 79%) [55].
Compared to the results obtained in this study, it is possible to see that the same tendency
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can be seen in ATPSs. The amount of PEG–lysine and PEG–histidine was almost the same
and the best performance was reached with PEG–arginine.
Furthermore, even though the affinity of the ligands to a particular type of RNA
seemed to be higher than for the pDNA itself, this was mostly overcome with the second
extraction. Extraction of the pDNA from the PEG-rich phase to an ammonium sulphate
phase yielded purified pDNA preparations without protein contamination and with a
residual presence of RNA. Since the final plasmid solutions had a considerable salt concen-
tration, their final recovery and concentration could be successfully achieved via centrifuge
filtration using Amicon Ultra-15 Centrifugal Filter Units (data not shown).
Finally, it was demonstrated that this affinity purification approach was suitable to be
implemented at a larger scale and could be used to purify pDNA from highly concentrated
crude cell lysates. In addition, the high affinity that was observed for a certain type of RNA
(not yet identified) opens perspectives for the utilisation of these ligands in the purification
of this biomolecule for RNA therapeutics, such as noncoding RNAs and mRNA [74,75].
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/life11111138/s1, Figure S1: Original Agarose gel electrophoresis (AGE) shown in Figure 2,
lanes 1–3: analysis of nucleic acids partitioning in systems composed by 16.2% (w/w) PEG 600–17.4%
(w/w) dextran 100 with 20% (w/w) of desalted bacterial lysate (pH = 7.5 or 8.5) and crescent concentra-
tions of PEG–amine. (L) Desalted lysate; (1–3) 6.3, 6.4 and 6.5% (w/w) PEG–amine. All concentrations
of affinity ligand are relative to the 16.2% (w/w) total PEG 600., Figure S2: Original Agarose gel
electrophoresis (AGE) shown in Figure 2, lanes 4–9: analysis of nucleic acids partitioning in systems
composed by 16.2% (w/w) PEG 600–17.4% (w/w) dextran 100 with 20% (w/w) of desalted bacterial
lysate (pH = 7.5 or 8.5) and crescent concentrations of PEG–lysine. (PP) Pure pDNA; (L) Desalted
lysate; (4–9) 0, 1.0, 1.05, 1.1, 1.15 and 1.2% (w/w) PEG–lysine. All concentrations of affinity ligand
are relative to the 16.2% (w/w) total PEG 600., Figure S3: Original Agarose gel electrophoresis (AGE)
shown in Figure 2, lanes 10–14: analysis of nucleic acids partitioning in systems composed by 16.2%
(w/w) PEG 600–17.4% (w/w) dextran 100 with 20% (w/w) of desalted bacterial lysate (pH = 7.5 or
8.5) and crescent concentrations of PEG–arginine. (L) Desalted lysate; (10–14) 0, 0.1, 0.2, 0.3 and
0.5% (w/w) PEG–arginine. All concentrations of affinity ligand are relative to the 16.2% (w/w) total
PEG 600., Figure S4: Original Agarose gel electrophoresis (AGE) shown in Figure 2, lanes 15–19:
analysis of nucleic acids partitioning in systems composed by 16.2% (w/w) PEG 600–17.4% (w/w)
dextran 100 with 20% (w/w) of desalted bacterial lysate (pH = 7.5 or 8.5) and crescent concentra-
tions of PEG–histidine. (L) Desalted lysate; (15–19) 0, 1, 1.3, 2 and 3% (w/w) PEG–histidine. All
concentrations of affinity ligand are relative to the 16.2% (w/w) total PEG 600., Figure S5: Original
Agarose gel electrophoresis (AGE) shown in Figure 3: analysis of nucleic acids partitioning in sys-
tems composed by (1) 16.2% (w/w) PEG 600–17.4% (w/w) dextran 100 with 20% (w/w) of desalted
bacterial lysate (pH = 7.5 or 8.5) with 6.5% PEG–amine and (2) 20% (w/w) PEG 600–15% (w/w)
ammonium sulphate systems. (L) Desalted lysate., Figure S6: Original Agarose gel electrophoresis
(AGE) shown in Figure 3: analysis of nucleic acids partitioning in systems composed by (1) 16.2%
(w/w) PEG 600–17.4% (w/w) dextran 100 with 20% (w/w) of desalted bacterial lysate (pH = 7.5 or
8.5) with 1.2% PEG–lysine and (2) 20% (w/w) PEG 600–15% (w/w) ammonium sulphate systems.
(PP) pure pDNA; (L) Desalted lysate., Figure S7: Original Agarose gel electrophoresis (AGE) shown
in Figure 3: analysis of nucleic acids partitioning in systems composed by (1) 16.2% (w/w) PEG
600–17.4% (w/w) dextran 100 with 20% (w/w) of desalted bacterial lysate (pH = 7.5 or 8.5) with 0.5%
PEG–arginine and (2) 20% (w/w) PEG 600–15% (w/w) ammonium sulphate systems. (L) Desalted
lysate., Figure S8: Original Agarose gel electrophoresis (AGE) shown in Figure 3: analysis of nucleic
acids partitioning in systems composed by (1) 16.2% (w/w) PEG 600–17.4% (w/w) dextran 100 with
20% (w/w) of desalted bacterial lysate (pH = 7.5 or 8.5) with 1.3% PEG–histidine and (2) 20% (w/w)
PEG 600–15% (w/w) ammonium sulphate systems. (L) Desalted lysate., Figure S9: Original SDS-
PAGE electrophoresis shown in Figure 4: analysis of total proteins partitioning in systems composed
by (1) 16.2% (w/w) PEG 600–17.4% (w/w) dextran 100 with 20% (w/w) of desalted bacterial lysate
(pH = 7.5 or 8.5) with 6.5% PEG–amine and (2) 20% (w/w) PEG 600–15% (w/w) ammonium sulphate
systems. (L) Desalted lysate., Figure S10: Original SDS-PAGE electrophoresis shown in Figure 4:
analysis of total proteins partitioning in systems composed by (1) 16.2% (w/w) PEG 600–17.4% (w/w)
dextran 100 with 20% (w/w) of desalted bacterial lysate (pH = 7.5 or 8.5) with 1.2% PEG–lysine and
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(2) 20% (w/w) PEG 600–15% (w/w) ammonium sulphate systems. (L) Desalted lysate., Figure S11:
Original SDS-PAGE electrophoresis shown in Figure 4: analysis of total proteins partitioning in
systems composed by (1) 16.2% (w/w) PEG 600–17.4% (w/w) dextran 100 with 20% (w/w) of desalted
bacterial lysate (pH = 7.5 or 8.5) with 0.5% PEG–arginine and (2) 20% (w/w) PEG 600–15% (w/w)
ammonium sulphate systems. (L) Desalted lysate., Figure S12: Original SDS-PAGE electrophoresis
shown in Figure 4: analysis of total proteins partitioning in systems composed by (1) 16.2% (w/w)
PEG 600–17.4% (w/w) dextran 100 with 20% (w/w) of desalted bacterial lysate (pH = 7.5 or 8.5)
with 1.3% PEG–histidine and (2) 20% (w/w) PEG 600–15% (w/w) ammonium sulphate systems.
(L) Desalted lysate., Figure S13: Original Agarose gel electrophoresis (AGE) shown in Figure 5(a):
analysis of nucleic acids partitioning in the scale-up experiments of systems composed by (1) 16.2%
(w/w) PEG 600–17.4% (w/w) dextran 100 with 20% (w/w) of desalted bacterial lysate (pH = 7.5 or
8.5) with 0.5% PEG–arginine and (2) 20% (w/w) PEG 600–15% (w/w) ammonium sulphate systems.
(L) Desalted lysate., Figure S14: Original Agarose gel electrophoresis (AGE) shown in Figure 5(b):
analysis of nucleic acids partitioning in the experiments of systems composed by (1) 16.2% (w/w)
PEG 600–17.4% (w/w) dextran 100 with 20% (w/w) of desalted bacterial lysate with high pDNA
production yield (pH = 7.5 or 8.5) with 0.5% PEG–arginine and (2) 20% (w/w) PEG 600–15% (w/w)
ammonium sulphate systems. (L*) Non-desalted lysate; (L) Desalted lysate.
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